Visus Therapeutics reported that the BRIO-I Phase 3 clinical trial met its primary and secondary endpoints, evaluating the safety and efficacy of BRIMOCHOL PF, a preservative-free ophthalmic solution for the treatment...
Search results for - visus
Visus posts positive Phase 3 data to treat presbyopia
Visus Therapeutics reported positive topline results from its Phase 3 pivotal BRIO-I trial, demonstrating highly statistically significant improvements in near and distance binocular visual acuity at multiple...
Verséa Holdings names Rob Sambursky as president to lead ophthalmic expansion
Verséa Holdings appointed Rob Sambursky, M.D., as president to support its corporate strategy and operations as well as lead the company’s expansion into the ophthalmic market. Verséa recently launched a new business...
